Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival

被引：19

作者：

Zabkiewicz, Catherine ^{[1
]}

Resaul, Jeyna ^{[1
]}

Hargest, Rachel ^{[1
]}

Jiang, Wen Guo ^{[1
]}

Ye, Lin ^{[1
]}

机构：

[1] Cardiff Univ, Sch Med, Cardiff China Med Res Collaborat, Henry Wellcome Bldg, Cardiff CF14 4XN, S Glam, Wales

来源：

CANCER GENOMICS & PROTEOMICS | 2017年 / 14卷 / 04期

关键词：

Follistatin; breast cancer; survival; ACTIVIN-A; BONE METASTASIS; CELL; GROWTH; TRANSCRIPTION; FLRG; ANTAGONISTS; MECHANISMS; CARCINOMA; PROTEINS;

D O I：

10.21873/cgp.20035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Activin and its antagonist follistatin (FST) have been implicated in several solid tumours. This study investigated the role of FST in breast cancer. Materials and Methods: FST expression was examined using reverse transcription polymerase chain reaction (RT-PCR), real-time quantitative polymerase chain reaction (qPCR) and immunohistochemistry in a cohort of breast cancer samples. Expression was correlated to pathological and prognostic parameters in our patient cohort. FST was overexpressed in MCF-7 cells and assays for growth and invasion were performed. Results: FST is expressed in breast tissue, in the cytoplasm of mammary epithelial cells. Expression was decreased in breast cancer tissue in comparison to normal mammary tissue. Over-expression of FST in vitro led to significantly increased growth rate and reduced invasion. Higher FST associates with lower-grade tumours and better survival. Conclusion: Our results suggest a role for FST as a suppressor of invasion and metastasis in breast cancer.

引用

页码：241 / 251

页数：11

共 34 条

[1] The bright and the dark sides of activin in wound healing and cancer [J].

Antsiferova, Maria ;

Werner, Sabine .

JOURNAL OF CELL SCIENCE, 2012, 125 (17) :3929-3937

[2] Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function [J].

Bartholin, L ;

Maguer-Satta, V ;

Hayette, S ;

Martel, S ;

Badoux, M ;

Corbo, L ;

Magaud, JP ;

Rimokh, R .

ONCOGENE, 2002, 21 (14) :2227-2235

[3] Activin-a signaling promotes epithelial–mesenchymal transition, invasion, and metastatic growth of breast cancer [J].

Bashir M. ;

Damineni S. ;

Mukherjee G. ;

Kondaiah P. .

npj Breast Cancer, 1 (1)

[4] Differential expression of follistatin and FLRG in human breast proliferative disorders [J].

Bloise, Enrrico ;

Couto, Henrique L. ;

Massai, Lauretta ;

Ciarmela, Pasquapina ;

Mencarelli, Marzia ;

Borges, Lavinia E. ;

Muscettola, Michela ;

Grasso, Giovanni ;

Amaral, Vania F. ;

Cassali, Geovanni D. ;

Petraglia, Felice ;

Reis, Fernando M. .

BMC CANCER, 2009, 9 :320

[5] Activin A mediates growth inhibition and cell cycle arrest through smads in human breast cancer cells [J].

Burdette, JE ;

Jeruss, JS ;

Kurley, SJ ;

Lee, EJ ;

Woodruff, TK .

CANCER RESEARCH, 2005, 65 (17) :7968-7975

[6] Activin and estrogen crosstalk regulates transcription in human breast cancer cells [J].

Burdette, Joanna E. ;

Woodruff, Teresa K. .

[7]

Couto HL, 2016, APPL IMMUNOHISTOCHEM

[8] Mechanisms of action of bone morphogenetic proteins in cancer [J].

Davis, Hayley ;

Raja, Erna ;

Miyazono, Kohei ;

Tsubakihara, Yutaro ;

Moustakas, Aristidis .

CYTOKINE & GROWTH FACTOR REVIEWS, 2016, 27 :81-92

[9] Activins and activin antagonists in hepatocellular carcinoma [J].

Deli, Alev ;

Kreidl, Emanuel ;

Santifaller, Stefan ;

Trotter, Barbara ;

Seir, Katja ;

Berger, Walter ;

Schulte-Hermann, Rolf ;

Rodgarkia-Dara, Chantal ;

Grusch, Michael .

WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (11) :1699-1709

[10] Antagonists of activin signaling: mechanisms and potential biological applications [J].

Harrison, CA ;

Gray, PC ;

Vale, WW ;

Robertson, DM .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2005, 16 (02) :73-78

← 1 2 3 4 →